React4Life
PrivateLast Round
Crowdfunding
Jul 25, 2022
Est. Valuation
$16.85M
Total Funding Raised
$1.38M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
React4Life operates in Healthcare & Life Sciences and is based in Italy. Its latest recorded funding round was a Crowdfunding round in July 2022.
React4Life is a biotechnology company that develops and commercializes MIVO® (Multi In Vitro Organ), an organ-on-chip platform for in-vitro testing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
React4Life Comparables
Compare React4Life with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BiomimX | 88% | |
| Beonchip | 88% | |
| AlveoliX AG | 87% |
For institutional investors. Book with your work email.
React4Life Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Crowdfunding | Jul 25, 2022 | ||||
| Grant | Jun 12, 2020 | ||||
| Grant | Jan 31, 2019 | ||||
| Angel | Jul 17, 2018 | ||||
| Accelerator | Nov 1, 2017 |
For institutional investors. Book with your work email.
React4Life Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Commission | Grant |
| Impact Hub Milano | Accelerator |
| FabriQ | Accelerator |
| Comune di Milano | Accelerator |
| European Union | Grant |
| UniCredit Start Lab | Angel |
| Regione Lombardia | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 2, 2026
Grew 30% QoQ, from 10 to 13 employees.
- May 26, 2026
Added CMT-DN, a Research & Development company, as a customer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
React4Life presents a poster at IPLASS 2026 demonstrating the MIVO(R) organ-on-chip platform for studying antitumor immunity and evaluating cell-based and nanoparticle-enabled immunotherapies.
- is_developingOct 28, 2026
React4Life could develop the model using MIVO technology to assess peripheral blood mononuclear cell recruitment toward tumor cells with or without anti-PVR and anti-Nectin-2 treatment.
For institutional investors. Book with your work email.
React4Life Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about React4Life's valuation, stock price, and market status.
Is React4Life a public or private company?
React4Life is a private company.
What is the current stock price of React4Life?
React4Life is a private company, so its shares have no public market price. Caplight tracks React4Life's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is React4Life worth (valuation)?
React4Life's valuation is estimated at $16.9M based on funding round data.
Can I buy React4Life stock?
React4Life shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was React4Life's last funding round?
React4Life's most recent funding round was Crowdfunding on July 25, 2022.
Who are the main investors in React4Life?
Key investors in React4Life include European Commission, Impact Hub Milano, FabriQ, Comune di Milano, European Union.
Will React4Life IPO soon?
No public IPO plans have been announced for React4Life.
How can I track React4Life secondary market activity?
Caplight tracks bids, offers, and trades in React4Life's shares on secondary markets.